Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial Lorenzo Falchi, Marcel Nijland, Huiqiang Huang, Kim M Linton, John F Seymour, Rong Tao, Michal Kwiatek, Abel Costa, Theodoros P Vassilakopoulos, Richard Greil, Ana Jiménez-Ubieto, Shane A Gangatharan, Ohad Benjamini, Catherine Thieblemont, Alessandra Tucci, Anna Elinder-Camburn, Arpad Illes, Jan Novak, Miguel A Pavlovsky, Andrew McDonald, Dok Hyun Yoon, Dai Maruyama, Gauri Sunkersett, Jian P Mei, Nabanita Mukherjee, Feng Zhu, Abualbishr Alshreef, Elena Favaro, Franck Morschhauser, Panagiotis Tsirigotis, Juliana Pereira, Sonia Gonzalez de Villambrosia, Jayr Schmidt Filho, Irit Avivi, Wojciech Jurczak, Olivier Casasnovas, Juan Miguel Bergua Burgues, Jianzhen Shen, Neta Goldschmidt, Maria Bouzani, Zsolt Nagy, Loic Ysebaert, Roch Houot, Benoit Tessoulin, Gandhi Laurent Damaj, Umberto Vitolo, Juan Manuel Sancho, Vinay Vanguru, Su-Peng Yeh, Xiaojing Yan, Ashley Freeman, Jean-Francois Larouche, Szabolcs Modok, Caterina Patti, Joaquin Sanchez Garcia, Ederson Roberto de Mattos, Patricia Walker, Jeong Ok Lee, Suguru Fukuhara, Yuko Mishima, Jie Jin, Zhengzi Qian, Russell Sterrett, Ronit Gurion, Natalia Rotter, David Belada, Katerina Kopeckova, Marek Trneny, Kamal Bouabdallah, Laure LeBras, Agathe Waultier, Stephanie Guidez, Pierre Feugier, Enrico Derenzini, Gloria Margiotta Casaluci, Blanca Sanchez Gonzalez, Javier Lopez Jiménez, Norma Gutierrez Gutierrez, Guillermo Rodriguez, Ana Carolina Caballero Gonzalez, Eva de Jongh, Wim Terpstra, Joost Vermaat, Tsai-Yun Chen, Hung-Lin Liu, Takayuki Ikezoe, Huijing Wu, Wenyu Li, Hongmei Jing, Adam Kittai, Catherine Diefenbach, Brad Hunter, Netanel Horowitz, Petra Pichler, Gabor Mikala, Andras Masszi, Lubos Drgona, Marie-Christine Ngirabacu, Ann Janssens, Romain Guieze, Eric Durot, Corinne Haioun, Johannes Duell, Enrico Schalk, Monica Tani, Ana Carla Oliveira Ramos, Raul Cordoba Mascunano, Carlos Grande Garcia, Adolfo de la Fuente, Michael Roost Clausen, Troels Thomsen, Ingemar Lagerlof, Inger Nijhof, Roderick Johnson, Danielle Leao Cordeiro de, Ricardo Bigni, Hock Choong Lai, Samar Issa, Dong-Yeop Shin, Cheng-Wei Chou, Hideki Goto, Takafumi Nakao, Caixia Li, Xiaolei Wei, Xudong Wei, Wenbin Qian, Shuo Ma, Vijayalakshmi Donthireddy, Catherine Diefenbach, Mark Fesler, Francisco Hernandez-Ilizaliturri, Moshe Levy, Abhijeet Kumar, Habte Yimer, David Berz, Fernando Cabanillas, Maya Koren Michowitz, Muhit Ozcan, Ozan Salim, Guray Saydam, Mehmet Turgut, Ozgur Mehtap, Mehmet Orhan Ayyildiz, Eirini Katodritou, Meletios-Athanasios Dimopoulos, Peter Rajnics, Vanessa Van Hende, Renaud Roufosse, Inge Vrelust, Nadine Morineau, Sylvain Choquet, Emmanuel Bachy, Julie Abraham, Frank Kroschinsky, Carmen Herling, Marco Ladetto, Potito Scalzulli, Andres Ferreri, Simone Ferrero, Stefan Hohaus, Stefan Kallert, Berit Johansson, Rinske Boersma, Eduard Libourel, Clara Klerk, Matthew Wilson, Rebecca Auer, Shankaranarayana Paneesha, Toby Eyre, David Lewis, Robert Ayto, Wendy Osborne, Luciana Andrea Guanchiale, Hun Chuah, Anita Shetty, Chan Cheah, Allanah Kilfoyle, Won Seog Kim, Ho-Jin Shin, Tomoaki Fujisaki, Takahiro Kumode, Kenji Ishitsuka, Junichiro Yuda, Hisayuki Yokoyama, Koji Kato, Toshio Kitawaki, Tadakazu Kondo, Youko Suehiro, Yoshiaki Ogawa, Hideyuki Nakazawa, Akihiro Tomita, Hirotoshi Kamata, Xun Lai, Yuerong Shuang, Guangxun Gao, Lihong Liu, Haiyan Yang, XiNan Cen Lancet, 2026 Background An unmet need persists for chemotherapy-free regimens that induce durable responses for relapsed or refractory follicular lymphoma. Lenalidomide and rituximab (R 2 ) is an accepted standard of care in this population. The EPCORE FL-1 trial aimed to evaluate the efficacy and safety of epcoritamab plus R 2 versus R 2 in participants with relapsed or refractory follicular lymphoma after at least one previous line of chemoimmunotherapy. Methods In this multicountry, open-label, phase 3 trial, participants were randomly allocated (1:1) to fixed-duration epcoritamab plus R 2 or R 2 for up to 12 cycles. Epcoritamab was administered weekly in cycles 1–3 and every 4 weeks in cycles 4–12, lenalidomide once daily during cycles 1–12 (days 1–21), and rituximab weekly during cycle 1 and monthly in cycles 2–5. The dual primary endpoints were overall response rate and progression-free survival by independent review committee. The data reported here are from a planned interim analysis carried out after 78% of progression-free survival events had occurred. This study is registered with ClinicalTrials.gov, NCT05409066, and EudraCT, 2021–000169–34, and is ongoing (closed to recruitment). Findings Out of 668 participants screened for eligibility across 189 academic and non-academic centres in 30 countries across Africa, Asia, Australia, Europe, North America, and South America, a total of 488 participants were randomly allocated, 243 to epcoritamab plus R 2 and 245 to R 2 . The trial met its dual primary endpoints, showing superiority of epcoritamab plus R 2 over R 2 in overall response rate and progression-free survival. With a median follow-up of 14·8 months (IQR 11·4–19·0), overall response rate was 95% (95% CI 92–97) with epcoritamab plus R 2 versus 79% (74–84; p<0·0001) with R 2 . Progression-free survival was longer with epcoritamab plus R 2 versus R 2 (hazard ratio 0·21 [95% CI 0·14–0·31], p<0·0001); estimated 16-month progression-free survival favoured epcoritamab plus R 2 (85·5% vs 40·2%). Grade 3 or higher adverse events were more frequent with epcoritamab plus R 2 (219 [90%] of 243 participants) versus R 2 (161 [68%] of 238 participants). Cytokine release syndrome was low grade with epcoritamab plus R 2 (grade 1 in 28 [21%] participants and grade 2 in seven [5%] participants) and manageable, and all events were resolved. Interpretation Epcoritamab plus R 2 resulted in significantly higher response rate and longer progression-free survival versus R 2 among participants with follicular lymphoma who had received at least one line of therapy. Epcoritamab plus R 2 had more grade 3 or higher adverse events versus R 2 . Adverse events were manageable and consistent with the established safety profiles of the individual components, with no new safety findings identified. These findings position epcoritamab plus R 2 as a new standard of care for second-line or subsequent treatment of follicular lymphoma. Funding AbbVie and Genmab.
Ewing sarcoma – current diagnostic and therapeutic approaches Anna Nohejlová-Medková, Pavel Pacas, Kateřina Kopečková Klinicka Onkologie, 2026 BACKGROUND: Ewing sarcoma belongs to the family of undifferentiated small round cell sarcomas of bone and soft tissue. It is characterized by a gene fusion involving EWSR1 and an ETS-family transcription factor gene. In 85-96% of cases, a specific chromosomal translocation results in the EWSR1-FLI1 fusion gene, whose product functions as an oncogene essential for tumorigenesis. Ewing sarcoma is most common in adolescents and young adults. It primarily affects the diaphyses of long bones, the pelvis, and the axial skeleton, although extraosseous involvement is not uncommon. This is a highly malignant neoplasm, and in most cases, micrometastases are already present at the time of diagnosis. The treatment is multimodal and includes local therapy (surgery and/or radiotherapy) and systemic chemotherapy. One of the greatest therapeutic challenges remains the long-term systemic control of the disease. To improve overall survival - especially in high-risk patients - innovative treatment strategies are essential, as the potential for intensifying chemotherapy has reached its limit due to treatment-related toxicity. Both diagnostic and therapeutic management should take place in specialized sarcoma centers. AIM: This article aims to provide an up-to-date overview of current diagnostic and therapeutic approaches in Ewing sarcoma.
Integrative miRNOMe profiling reveals the miR-195-5p–CHEK1 axis and its impact on luminal breast cancer outcomes Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček Molecular Oncology, 2025 The luminal subtype (estrogen receptor‐positive, ER+) is the most common and the most heterogeneous type of breast carcinoma (BC) in women. During our study, we determined expression levels of all microRNAs (miRNome) in 101 ER+ BC samples and identified 25 miRNAs being associated with proliferative markers. Using comprehensive in silico analyses we prioritized CHEK1, CDC25A, and CCNE1 as candidate genes affecting the proliferation of ER+ BC, with two microRNAs from the miR‐497∼195 cluster identified as their potential regulators. In a cohort of 217 patients, we found a significant association between high expression of CHEK1 and shorter relapse‐free survival (RFS) in luminal BC patients treated with adjuvant chemotherapy, especially in patients with luminal A subtype. In patients treated with neoadjuvant therapy, the opposite role for RFS was observed for hsa‐miR‐195‐5p. Subsequently, we confirmed the potency of hsa‐miR‐195‐5p to inhibit the expression of CHEK1 in vitro. Moreover, the specific Chk1 inhibitor rabusertib (LY2603618) significantly enhanced the efficacy of doxorubicin in both ER+ and ER‐ cell lines. In summary, we have identified the association of a specific miRNA profile with highly proliferative luminal BCs and demonstrated the ability of hsa‐miR‐195‐5p to inhibit CHEK1 expression in BC in vitro, underlining the importance of CHEK1 expression and its inhibition for prognosis and treatment of patients with luminal BCs.
Molecular impact of NOTCH signaling dysregulation on ovarian cancer progression, chemoresistance, and taxane response Kamila Koucka, Alzbeta Spalenkova, Karolina Seborova, Tereza Tesarova, Marie Ehrlichova, Ivona Krus, Petr Holy, Lukas Rob, Martin Hruda, Jiri Bouda, Alena Bartakova, Vendula Smoligova, Iwao Ojima, Lei Chen, Hersch Bendale, Marcela Mrhalova, Katerina Kopeckova, Pavel Soucek, Radka Vaclavikova Biomedicine and Pharmacotherapy, 2025 Patients with epithelial ovarian cancer (EOC) face high mortality due to late diagnosis, recurrence, metastasis, and drug resistance. The NOTCH signaling pathway plays a critical role in cancer progression. This study analyzed NOTCH pathway deregulation in EOC patients and its response to taxane treatment in vitro and in vivo . In tumor cells of EOC patients, a significant upregulation of NOTCH1/3/4 and JAG2 and a downregulation of the NOTCH2 gene were found. The observed high levels of NOTCH3 mRNA were also confirmed at the protein level. In contrast, we observed a significant association of low NOTCH4 expression with the presence of peritoneal metastasis and shortened platinum-free interval. In the resistant in vitro cell line model, significant upregulation of NOTCH signaling pathway, namely NOTCH3 , was observed after treatment with experimental Stony Brook taxanes (SB-Ts), with high efficacy against paclitaxel-resistant ovarian tumor cells. The administration of SB-Ts also caused NOTCH3 upregulation in an effective combination regimen with paclitaxel in comparison to paclitaxel alone and untreated control in the in vivo cell-derived xenograft mouse model of resistant ovarian cancer. Knockdown of the NOTCH3 gene caused higher sensitivity of resistant cells to taxanes, suggesting that NOTCH3-specific inhibition may potentially bring therapeutic benefits in resistant ovarian carcinoma. Based on our results, we suggest the NOTCH3 gene as a potential target for preclinical studies on resistant ovarian tumors. The current study also highlights the NOTCH4 gene as a potential predictive biomarker of therapeutic response in ovarian cancer. • Epithelial ovarian carcinoma (EOC) remains challenging due to frequent resistance. • Low NOTCH4 gene expression was associated with poor EOC response and prognosis. • Treatment of taxanes caused in vitro/in vivo upregulation of NOTCH3 . • NOTCH3 knockdown increased sensitivity to taxanes in resistant ovarian cancer cells. • NOTCH3 seems to be a potential drug target in the therapy of resistant EOC.
Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer Rossella Elisei, Lori J. Wirth, Jaume Capdevila, Ana O. Hoff, Makoto Tahara, et al. Thyroid, 2025 Background: Progression-free survival (PFS) may not fully capture the impact of treatment on patients, especially in cancers with longer natural histories and thus, could be complemented by robust measures of patient-reported tolerability (PRT). We report the use of a novel, quantifiable PRT metric as a multiplicity-controlled endpoint to support regulatory and clinical decision-making for selpercatinib use. Comparative PRT was assessed in LIBRETTO-531 (NCT04211337), a randomized phase 3 trial of selpercatinib versus vandetanib/cabozantinib (control) in advanced RET -mutant medullary thyroid cancer (MTC). Patients and Methods: Patients were self-administered the single Functional Assessment of Cancer Therapy item GP5: “I am bothered by side effects” weekly, and scores were dichotomized into “low” (0–2) and “high” (3–4) side-effect burden. PRT measured the proportion of time on treatment (PTT) with “high” side-effect burden for each patient. Comparative PRT was tested at a two-sided significance level of 0.05, conditional on achieving significance for efficacy endpoints. Complementary patient-reported outcomes included health-related quality of life (HRQoL) and symptomatic adverse events self-administered at baseline and at different intervals post-baseline during treatment period. Results: In the tolerability evaluable population (N = 242; selpercatinib n = 161 and control n = 81 [56 received cabozantinib, 25 received vandetanib]), patients on selpercatinib had significantly better PRT with lower PTT with “high side-effect burden” than control (8% vs. 24%, p < 0.0001). Post-baseline compliance rates for PRO questionnaires were generally greater than 80% in both treatment groups. Patients on selpercatinib reported significantly less PTT with HRQoL impairment across physical (36% vs. 52%), role (2% vs. 11%), cognitive (4% vs. 8%), emotional (6% vs. 11%), and social (2% vs. 8%) function (all p < 0.01); and significantly less PTT with severe diarrhea (5% vs. 38%), fatigue (6% vs. 21%), taste change (3% vs. 15%), decreased appetite (2% vs. 15%), and hand-foot syndrome (2% vs. 9%) (all p < 0.001). Conclusion: This study demonstrated superior PRT for selpercatinib compared with control in patients with RET -mutant MTC, further supporting selpercatinib use as the first-line treatment for patients with advanced RET -mutant MTC. Comparative PRT deserves further adoption as a complement to traditional endpoints in future randomized-controlled trials.
DIABETES INSIPIDUS AS A RARE COMPLICATION OF CANCER TREATMENT Diabetologie Metabolismus Endokrinologie Vyziva, 2025
Outcome of patients with diffuse large B-cell lymphoma and testicular involvement – real world data Heidi Mocikova, Andrea Janikova, Alice Sykorova, Vit Prochazka, Jan Pirnos, Juraj Duras, Katerina Kopeckova, Katerina Steinerova, Robert Pytlik, Petra Blahovcova, David Salek, Tomas Kozak, Veronika Bachanova, David Belada Annals of Hematology, 2025 Patients with testicular lymphoma are at an increased risk of central nervous system (CNS) disease. Optimal strategy for CNS relapse prevention is unknown. We analyzed treatment strategies, cumulative incidence of CNS relapse and prognosis in 229 patients with diffuse large B-cell lymphoma (DLBCL) and testicular involvement: 157 primary testicular lymphomas (PTL) in clinical stages IE/IIE and 72 patients in advanced stages (T-DLBCL) IIIE/IV. Treatments for PTL vs. T-DLBCL included: rituximab-based chemotherapy (80.9% vs. 90.3%), orchiectomy (94.3% vs. 65.3%) and contralateral testicular irradiation (59.8% vs. 44.4%). Majority (84.3%) received CNS prophylaxis with similar rates of prophylactic methotrexate (intravenous 19.1% vs. 16.6%, intrathecal 40.8% vs. 40.4%, or both 24.2% vs. 27.8%) between PTL and T-DLBCL (p = 0.89). Median follow-up was 51.8 months. CNS relapses occurred in 14 (6.1%) of 63 relapsing patients. The 5-year cumulative incidence of CNS relapse in PTL was 4.5% and in T-DLBCL 12.1%. Median time to CNS relapse was 21.9 months. In univariate analyses, orchiectomy was the single significant factor associated with lower risk of CNS relapse in PTL (HR = 0.11 [95% CI, 0-0.124], p = 0.001). Rituximab significantly reduced CNS relapse risk in T-DLBCL (HR = 0.1002, p = 0.0005). Median progression-free survival (PFS) and overall survival (OS) following CNS relapse was dismal in T-DLBCL compared to PTL (PFS 1.6 vs. 37.8 months, p = 0.04 and OS 2.3 vs. 37.8 months, p = 0.05). This study confirmed a favorable impact of rituximab in prevention of CNS relapse in T-DLBCL. Methotrexate prophylaxis did not alter CNS relapse risk. Prognosis of CNS relapse is particularly poor in T-DLBCL.
Spatial immunoprofiling of retroperitoneal leiomyosarcomas reveals intratumoral heterogeneity in immune cell infiltration, checkpoint molecule expression, and tertiary lymphoid structures Iva Benesova, Jan Balko, Vira Tovazhnianska, Michal Rataj, Robert Lischke, Jirina Bartunkova, Katerina Kopeckova, Tomas Buchler, Winan van Houdt, Yvonne Schrage, David Moura, Javier Martin Broto, Zuzana Ozaniak Strizova, Andrej Ozaniak Annals of Medicine, 2025 INTRODUCTION: Leiomyosarcoma (LMS) is a rare, aggressive cancer with limited treatment options at the metastatic stage. The response to immune checkpoint inhibitors (ICIs) is inconsistent, likely due to intratumoral heterogeneity, which is more pronounced in large tumours such as retroperitoneal LMS. METHODS: This study examined heterogeneity in four large treatment-naive LMS tumours (ten samples per tumour) by analysing immune cells, tertiary lymphoid structures (TLSs), checkpoint molecules, and cytokine secretion across different tumour regions. RESULTS: Significant region-dependent differences were observed in immune components, with TLSs present only at tumour margins and inconsistently across samples from the same tumour. Expression levels of programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) varied within individual tumours, and shared immune patterns were identified in specific regions, including elevated indoleamine 2,3-dioxygenase 1, absence of a particular macrophage subpopulation, and reduced PD-1 and lymphocyte activation gene 3 (LAG-3) expression at organ-adjacent margins. Anti-LAG-3 blockade altered cytokine and checkpoint molecule levels in a region-specific manner. CONCLUSION: These findings highlight substantial intratumoral heterogeneity, which may contribute to the variable response to ICI therapy. As immune checkpoint molecule expression influences treatment eligibility, multiple biopsies from different tumour regions may be necessary to assess immune infiltration accurately and guide therapy decisions.
Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression Petr Holý, Viktor Hlaváč, Karolína Šeborová, Simona Šůsová, Tereza Tesařová, Lukáš Rob, Martin Hruda, Jiří Bouda, Alena Bartáková, Marcela Mrhalová, Kateřina Kopečková, Mohammad Al Obeed Allah, Jiří Špaček, Iva Sedláková, Pavel Souček, Radka Václavíková International Journal of Cancer, 2024 High‐grade serous ovarian carcinoma (HGSC) is the most common subtype of ovarian cancer and is among the most fatal gynecological malignancies worldwide, due to late diagnosis at advanced stages and frequent therapy resistance. In 47 HGSC patients, we assessed somatic and germline genetic variability of a custom panel of 144 known or suspected HGSC‐related genes by high‐coverage targeted DNA sequencing to identify the genetic determinants associated with resistance to platinum‐based therapy. In the germline, the most mutated genes were DNAH14 (17%), RAD51B (17%), CFTR (13%), BRCA1 (11%), and RAD51 (11%). Somatically, the most mutated gene was TP53 (98%), followed by CSMD1/2/3 (19/19/36%), and CFTR (23%). Results were compared with those from whole exome sequencing of a similar set of 35 HGSC patients. Somatic variants in TP53 were also validated using GENIE data of 1287 HGSC samples. Our approach showed increased prevalence of high impact somatic and germline mutations, especially those affecting splice sites of TP53, compared to validation datasets. Furthermore, nonsense TP53 somatic mutations were negatively associated with patient survival. Elevated TP53 transcript levels were associated with platinum resistance and presence of TP53 missense mutations, while decreased TP53 levels were found in tumors carrying mutations with predicted high impact, which was confirmed in The Cancer Genome Atlas data (n = 260). Targeted DNA sequencing of TP53 combined with transcript quantification may contribute to the concept of precision oncology of HGSC. Future studies should explore targeting the p53 pathway based on specific mutation types and co‐analyze the expression and mutational profiles of other key cancer genes.
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer Julien Hadoux, Rossella Elisei, Marcia S. Brose, Ana O. Hoff, Bruce G. Robinson, Ming Gao, Barbara Jarzab, Pavel Isaev, Katerina Kopeckova, Jonathan Wadsley, Dagmar Führer, Bhumsuk Keam, Stéphane Bardet, Eric J. Sherman, Makoto Tahara, Mimi I. Hu, Ravinder Singh, Yan Lin, Victoria Soldatenkova, Jennifer Wright, Boris Lin, Patricia Maeda, Jaume Capdevila, Lori J. Wirth New England Journal of Medicine, 2023
Pencil-beam scanning proton therapy for the treatment of glomus jugulare tumours Jiří Kubeš, Vladimír Vondráček, Michal Andrlik, Matěj Navrátil, Silvia Sláviková, Daniel Klika, Alexandra Haas, Kateřina Dědečková, Kateřina Kopečková, Barbora Ondrová, Eliška Rotnáglová, Štěpán Vinakurau, Alexander Grebenyuk, Jozef Rosina Journal of Medical Radiation Sciences, 2022
Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up ☆ P.G. Casali, J.Y. Blay, N. Abecassis, J. Bajpai, S. Bauer, R. Biagini, S. Bielack, S. Bonvalot, I. Boukovinas, J.V.M.G. Bovee, K. Boye, T. Brodowicz, A. Buonadonna, E. De Álava, A.P. Dei Tos, X.G. Del Muro, A. Dufresne, M. Eriksson, A. Fedenko, V. Ferraresi, A. Ferrari, A.M. Frezza, S. Gasperoni, H. Gelderblom, F. Gouin, G. Grignani, R. Haas, A.B. Hassan, N. Hindi, P. Hohenberger, H. Joensuu, R.L. Jones, C. Jungels, P. Jutte, B. Kasper, A. Kawai, K. Kopeckova, D.A. Krákorová, A. Le Cesne, F. Le Grange, E. Legius, A. Leithner, A. Lopez-Pousa, J. Martin-Broto, O. Merimsky, C. Messiou, A.B. Miah, O. Mir, M. Montemurro, C. Morosi, E. Palmerini, M.A. Pantaleo, R. Piana, S. Piperno-Neumann, P. Reichardt, P. Rutkowski, A.A. Safwat, C. Sangalli, M. Sbaraglia, S. Scheipl, P. Schöffski, S. Sleijfer, D. Strauss, S.J. Strauss, K Sundby Hall, A. Trama, M. Unk, M.A.J. van de Sande, W.T.A. van der Graaf, W.J. van Houdt, T. Frebourg, A. Gronchi, S. Stacchiotti Annals of Oncology, 2022
Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up ☆ S.J. Strauss, A.M. Frezza, N. Abecassis, J. Bajpai, S. Bauer, R. Biagini, S. Bielack, J.Y. Blay, S. Bolle, S. Bonvalot, I. Boukovinas, J.V.M.G. Bovee, K. Boye, B. Brennan, T. Brodowicz, A. Buonadonna, E. de Álava, A.P. Dei Tos, X. Garcia del Muro, A. Dufresne, M. Eriksson, F. Fagioli, A. Fedenko, V. Ferraresi, A. Ferrari, N. Gaspar, S. Gasperoni, H. Gelderblom, F. Gouin, G. Grignani, A. Gronchi, R. Haas, A.B. Hassan, S. Hecker-Nolting, N. Hindi, P. Hohenberger, H. Joensuu, R.L. Jones, C. Jungels, P. Jutte, L. Kager, B. Kasper, A. Kawai, K. Kopeckova, D.A. Krákorová, A. Le Cesne, F. Le Grange, E. Legius, A. Leithner, A. López Pousa, J. Martin-Broto, O. Merimsky, C. Messiou, A.B. Miah, O. Mir, M. Montemurro, B. Morland, C. Morosi, E. Palmerini, M.A. Pantaleo, R. Piana, S. Piperno-Neumann, P. Reichardt, P. Rutkowski, A.A. Safwat, C. Sangalli, M. Sbaraglia, S. Scheipl, P. Schöffski, S. Sleijfer, D. Strauss, K. Sundby Hall, A. Trama, M. Unk, M.A.J. van de Sande, W.T.A. van der Graaf, W.J. van Houdt, T. Frebourg, R. Ladenstein, P.G. Casali, S. Stacchiotti Annals of Oncology, 2021
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ A. Gronchi, A.B. Miah, A.P. Dei Tos, N. Abecassis, J. Bajpai, S. Bauer, R. Biagini, S. Bielack, J.Y. Blay, S. Bolle, S. Bonvalot, I. Boukovinas, J.V.M.G. Bovee, K. Boye, B. Brennan, T. Brodowicz, A. Buonadonna, E. De Álava, X.G. Del Muro, A. Dufresne, M. Eriksson, F. Fagioli, A. Fedenko, V. Ferraresi, A. Ferrari, A.M. Frezza, S. Gasperoni, H. Gelderblom, F. Gouin, G. Grignani, R. Haas, A.B. Hassan, S. Hecker-Nolting, N. Hindi, P. Hohenberger, H. Joensuu, R.L. Jones, C. Jungels, P. Jutte, L. Kager, B. Kasper, A. Kawai, K. Kopeckova, D.A. Krákorová, A. Le Cesne, F. Le Grange, E. Legius, A. Leithner, A. Lopez-Pousa, J. Martin-Broto, O. Merimsky, C. Messiou, O. Mir, M. Montemurro, B. Morland, C. Morosi, E. Palmerini, M.A. Pantaleo, R. Piana, S. Piperno-Neumann, P. Reichardt, P. Rutkowski, A.A. Safwat, C. Sangalli, M. Sbaraglia, S. Scheipl, P. Schöffski, S. Sleijfer, D. Strauss, S. Strauss, K. Sundby Hall, A. Trama, M. Unk, M.A.J. van de Sande, W.T.A. van der Graaf, W.J. van Houdt, T. Frebourg, P.G. Casali, S. Stacchiotti Annals of Oncology, 2021
Nanodrugs used in cancer therapy Katerina Kopeckova, Tomas Eckschlager, Jakub Sirc, Radka Hobzova, Johana Plch, Jan Hrabeta, Jiri Michalek Biomedical Papers, 2019
Corrections to “Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up” (Annals of Oncology (2018) 29(S4) (iv68–iv78), (S0923753419316916), (10.1093/annonc/mdy095)) P.G. Casali, N. Abecassis, H.T. Aro, S. Bauer, R. Biagini, S. Bielack, S. Bonvalot, I. Boukovinas, J V M G Bovee, T. Brodowicz, J.M. Broto, A. Buonadonna, E. De Álava, A.P. Dei Tos, X.G. Del Muro, P. Dileo, M. Eriksson, A. Fedenko, V. Ferraresi, A. Ferrari, S. Ferrari, A.M. Frezza, S. Gasperoni, H. Gelderblom, T. Gil, G. Grignani, A. Gronchi, R.L. Haas, B. Hassan, P. Hohenberger, R. Issels, H. Joensuu, R.L. Jones, I. Judson, P. Jutte, S. Kaal, B. Kasper, K. Kopeckova, D.A. Krákorová, A. Le Cesne, I. Lugowska, O. Merimsky, M. Montemurro, M.A. Pantaleo, R. Piana, P. Picci, S. Piperno-Neumann, A.L. Pousa, P. Reichardt, M.H. Robinson, P. Rutkowski, A.A. Safwat, P. Schöffski, S. Sleijfer, S. Stacchiotti, K. Sundby Hall, M. Unk, F. Van Coevorden, W.T.A. van der Graaf, J. Whelan, E. Wardelmann, O. Zaikova, J.Y. Blay Annals of Oncology, 2018
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up P.G. Casali, N. Abecassis, S. Bauer, R. Biagini, S. Bielack, S. Bonvalot, I. Boukovinas, J.V.M.G. Bovee, T. Brodowicz, J.M. Broto, A. Buonadonna, E. De Álava, A.P. Dei Tos, X.G. Del Muro, P. Dileo, M. Eriksson, A. Fedenko, V. Ferraresi, A. Ferrari, S. Ferrari, A.M. Frezza, S. Gasperoni, H. Gelderblom, T. Gil, G. Grignani, A. Gronchi, R.L. Haas, A. Hannu, B. Hassan, P. Hohenberger, R. Issels, H. Joensuu, R.L. Jones, I. Judson, P. Jutte, S. Kaal, B. Kasper, K. Kopeckova, D.A. Krákorová, A. Le Cesne, I. Lugowska, O. Merimsky, M. Montemurro, M.A. Pantaleo, R. Piana, P. Picci, S. Piperno-Neumann, A.L. Pousa, P. Reichardt, M.H. Robinson, P. Rutkowski, A.A. Safwat, P. Schöffski, S. Sleijfer, S. Stacchiotti, K. Sundby Hall, M. Unk, F. Van Coevorden, W. Van der Graaf, J. Whelan, E. Wardelmann, O. Zaikova, J.Y. Blay Annals of Oncology, 2018
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up P.G. Casali, N. Abecassis, S. Bauer, R. Biagini, S. Bielack, S. Bonvalot, I. Boukovinas, J V M G Bovee, T. Brodowicz, J.M. Broto, A. Buonadonna, E. De Álava, A.P. Dei Tos, X.G. Del Muro, P. Dileo, M. Eriksson, A. Fedenko, V. Ferraresi, A. Ferrari, S. Ferrari, A.M. Frezza, S. Gasperoni, H. Gelderblom, T. Gil, G. Grignani, A. Gronchi, R.L. Haas, A. Hannu, B. Hassan, P. Hohenberger, R. Issels, H. Joensuu, R.L. Jones, I. Judson, P. Jutte, S. Kaal, B. Kasper, K. Kopeckova, D.A. Krákorová, A. Le Cesne, I. Lugowska, O. Merimsky, M. Montemurro, M.A. Pantaleo, R. Piana, P. Picci, S. Piperno-Neumann, A.L. Pousa, P. Reichardt, M.H. Robinson, P. Rutkowski, A.A. Safwat, P. Schöffski, S. Sleijfer, S. Stacchiotti, K. Sundby Hall, M. Unk, F. Van Coevorden, W. Van der Graaf, J. Whelan, E. Wardelmann, O. Zaikova, J.Y. Blay Annals of Oncology, 2018
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up P.G. Casali, N. Abecassis, H.T. Aro, S. Bauer, R. Biagini, S. Bielack, S. Bonvalot, I. Boukovinas, J V M G Bovee, T. Brodowicz, J.M. Broto, A. Buonadonna, E. De Álava, A.P. Dei Tos, X.G. Del Muro, P. Dileo, M. Eriksson, A. Fedenko, V. Ferraresi, A. Ferrari, S. Ferrari, A.M. Frezza, S. Gasperoni, H. Gelderblom, T. Gil, G. Grignani, A. Gronchi, R.L. Haas, B. Hassan, P. Hohenberger, R. Issels, H. Joensuu, R.L. Jones, I. Judson, P. Jutte, S. Kaal, B. Kasper, K. Kopeckova, D.A. Krákorová, A. Le Cesne, I. Lugowska, O. Merimsky, M. Montemurro, M.A. Pantaleo, R. Piana, P. Picci, S. Piperno-Neumann, A.L. Pousa, P. Reichardt, M.H. Robinson, P. Rutkowski, A.A. Safwat, P. Schöffski, S. Sleijfer, S. Stacchiotti, K. Sundby Hall, M. Unk, F. Van Coevorden, W.T.A. van der Graaf, J. Whelan, E. Wardelmann, O. Zaikova, J.Y. Blay Annals of Oncology, 2018
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up P.G. Casali, S. Bielack, N. Abecassis, H.T. Aro, S. Bauer, R. Biagini, S. Bonvalot, I. Boukovinas, J V M G Bovee, B. Brennan, T. Brodowicz, J.M. Broto, L. Brugières, A. Buonadonna, E. De Álava, A.P. Dei Tos, X.G. Del Muro, P. Dileo, C. Dhooge, M. Eriksson, F. Fagioli, A. Fedenko, V. Ferraresi, A. Ferrari, S. Ferrari, A.M. Frezza, N. Gaspar, S. Gasperoni, H. Gelderblom, T. Gil, G. Grignani, A. Gronchi, R.L. Haas, B. Hassan, S. Hecker-Nolting, P. Hohenberger, R. Issels, H. Joensuu, R.L. Jones, I. Judson, P. Jutte, S. Kaal, L. Kager, B. Kasper, K. Kopeckova, D.A. Krákorová, R. Ladenstein, A. Le Cesne, I. Lugowska, O. Merimsky, M. Montemurro, B. Morland, M.A. Pantaleo, R. Piana, P. Picci, S. Piperno-Neumann, A.L. Pousa, P. Reichardt, M.H. Robinson, P. Rutkowski, A.A. Safwat, P. Schöffski, S. Sleijfer, S. Stacchiotti, S.J. Strauss, K. Sundby Hall, M. Unk, F. Van Coevorden, W.T.A. van der Graaf, J. Whelan, E. Wardelmann, O. Zaikova, J.Y. Blay Annals of Oncology, 2018
Sunitib in adjuvant treatment for renal cell carcinoma Onkologie Czech Republic, 2017
Effectiveness of human cytochrome P450 3A4 present in liposomal and microsomal nanoparticles in formation of covalent DNA adducts by ellipticine Neuroendocrinology Letters, 2016
